Join the Invokana group to help and get support from people like you.
Invokana News (Page 2)
FDA Medwatch Alert: SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood
ISSUE: FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood...
FDA Approves Invokamet (canagliflozin/metformin) for Type 2 Diabetes
RARITAN, N.J., August 8, 2014 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet, a fixed dose therapy combining canagliflozin and m...
Further information
Related condition support groups
Diabetes, Type 2, Cardiovascular Risk Reduction